Penn Pharma

Origins

Penn Pharmaceuticals was set up Penn, Buckinghamshire in 1979 by Sir Roger Jones because he was frustrated with the slow rate of progress of many trials. Moving to Tredegar, Gwent in 1986 he detected a gap in the market for a company that specialised in providing, with greater efficiency, drugs and placebos for patients, as well as bringing all the analytical methods up to speed. Sir Roger sold the company to the current team via a management buyout in 2000 which paved the way for the £67M Tertiary MBO by the current management team.

Success Factor

From the world's leading innovators to the industry's market leaders, the quality and variety of Penn’s customer base is enviable. Penn Pharma is continually challenged by client requirements, changes in regulation and developments within the industry. Its depth of knowledge and wealth of experience helps rise to these challenges and provide time saving and cost effective solutions for clients. Its flexible and customised approach enables clients to stay in control of their project. Penn Pharma’s single site facility reduces communication and timeline issues and clients can choose to utilise Penn Pharma as a complete development partner and benefit from the our full range of services and experience or choose any of core services as a stand-alone offering. lt is this flexibility and personal approach that differentiates Penn Pharm from its competitors. From Its UK location, Penn Pharma is uniquely positioned to offer non-EU clients a portal into Europe for the importation and distribution of their clinical trial and commercial material and have six full time QPs (Qualified Person) on site. With global reach through an international sales force based in the UK as well as Penn Inc. as the Americas sales division & Penn Japan which were formed in 2007, distribution network and strategic alliances, many international companies already trust Penn Pharma to get their products to market.

The Future

The last two years saw Penn adding a High Potency manufacturing capability and Steriles partnership, a new storage facility based in Oakdale, ISO14001 re-accreditation, Site Development and operational efficiency programs implemented, A fully validated electronic inventory management system, a new cold store tripling their capacity in this area and Xcelodose Precision Powder Micro-dosing equipment implemented. The company will continue to target export growth through a strategy of continuing to expand facilities and resources, regular overseas visits to current and potential clients by both technical and business development staff, accompanied by a programme of international exhibitions, seminars and client visits to Wales. Penn’s key objectives is to provide outstanding experts in their field to its clients, "Keep our promises" and deliver projects to an extremely high Quality and to time and to cost. The overall aim is to facilitate our Clients to achieve success in developing and selling complex & difficult drug formulations.